2022-500774-34-00已完成1 期
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Daniel Peris
Scientific
Noucor Health S.A.
研究点 (9)
Loading locations...
相似试验
招募中
1 期
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma2023-504571-25-00F. Hoffmann-La Roche AG180
已完成
1 期
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Standard-of-Care Chemotherapy in Patients with Locally Advanced or Metastatic Solid Tumors2022-502615-11-00Genentech Inc., Genentech Inc.35